Delaware
|
000-51481
|
13-3986004
|
(State or Other
|
(Commission File
|
(I.R.S. Employer
|
Jurisdiction of
|
Number)
|
Identification No.)
|
Incorporation)
|
|
|
|
5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
|
19044
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
□
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
SSKN
|
The NASDAQ Stock Market LLC
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
Date: May 12, 2020
|
By:
|
/s/ Matthew C. Hill
|
|
|
|
Matthew C. Hill
|
|
|
|
Chief Financial Officer
|
|
•
|
Total revenue for the first quarter of 2020 was $6.7 million, a decrease of 10.1% over total revenues for the first quarter of 2019 as our overseas equipment revenue was impacted by
COVID-19.
|
•
|
Total global XTRAC® recurring revenue in the first quarter of 2020 was $5.7 million, up 7.3% over first quarter 2019 total global XTRAC recurring revenues.
|
•
|
Total gross margins and recurring gross margins were 65.4% and 68.4%, respectively, an increase of 3.8% and 2.2%, respectively, as compared to first quarter 2019.
|
•
|
Net loss was $1.0 million, a decrease of 22.4% from a net loss of $1.3 million in the first quarter 2019.
|
•
|
Domestic and International recurring installed base of 822 and 16 XTRAC devices, respectively, an increase of 2 and 6 devices, respectively.
|
•
|
A peer reviewed study published in Journal of Drugs in Dermatology (April 2020) showing 92% of participants in study achieved reduction in
mPASI score of 75% or more after receiving Optimal Therapeutic Dose Therapy with the XTRAC Multi-Micro Dose® diagnostic tip for treatment of plaque psoriasis.
|
•
|
Cash and cash equivalents and restricted cash at March 31, 2020 was $15.6 million.
|
•
|
The Company received, on April 21, 2020, a $2.0 million forgivable loan under the SBA Payroll Protection Plan (the “PPP loan”).
|
For the Three Months Ended March 31,
|
||||||||
2020
|
2019
|
|||||||
Net Loss
|
$
|
(1,035
|
)
|
$
|
(1,333
|
)
|
||
Adjustments:
|
||||||||
Depreciation/amortization
|
1,117
|
1,297
|
||||||
Income taxes
|
88
|
(43
|
)
|
|||||
Interest (income) expense, net
|
(1
|
)
|
135
|
|||||
Non-GAAP EBITDA
|
169
|
56
|
||||||
Stock compensation
|
430
|
323
|
||||||
Non-GAAP adjusted EBITDA
|
$
|
599
|
$
|
379
|
Date:
|
Tuesday, May 12
|
Time:
|
8:30 am Eastern Time
|
Toll Free:
|
877-451-6152
|
International:
|
201-389-0879
|
Israel:
|
1 809 406 247
|
Passcode:
|
13703218
|
Webcast:
|
www.strataskinsciences.com
|
Matthew Hill, Chief Financial Officer
|
Matthew Picciano, Managing Director
|
|
STRATA Skin Sciences, Inc.
|
LifeSci Advisors, LLC
|
|
215-619-3200
|
646-889-1200
|
|
ir@strataskin.com
|
mpicciano@lifesciadvisors.com
|
March 31, 2020
|
December 31, 2019
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
8,150
|
$
|
8,129
|
||||
Restricted cash
|
7,481
|
7,500
|
||||||
Accounts receivable, net of allowance for doubtful accounts of $186 and $184, respectively
|
3,208
|
4,386
|
||||||
Inventories
|
3,471
|
3,027
|
||||||
Prepaid expenses and other current assets
|
487
|
513
|
||||||
Total current assets
|
22,797
|
23,555
|
||||||
Property and equipment, net
|
5,379
|
5,369
|
||||||
Operating lease right-of-use assets, net
|
1,235
|
1,314
|
||||||
Intangible assets, net
|
7,503
|
7,955
|
||||||
Goodwill
|
8,803
|
8,803
|
||||||
Other assets
|
330
|
347
|
||||||
Total assets
|
$
|
46,047
|
$
|
47,343
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Note payable
|
$
|
7,275
|
$
|
7,275
|
||||
Accounts payable
|
2,102
|
1,880
|
||||||
Other accrued liabilities
|
5,150
|
5,134
|
||||||
Current portion of operating lease liabilities
|
343
|
313
|
||||||
Deferred revenues
|
1,934
|
2,832
|
||||||
Total current liabilities
|
16,804
|
17,434
|
||||||
Long-term liabilities:
|
||||||||
Deferred tax liability
|
88
|
-
|
||||||
Long-term operating lease liabilities, net
|
988
|
1,078
|
||||||
Other liabilities
|
119
|
178
|
||||||
Total liabilities
|
17,999
|
18,690
|
||||||
Commitments and contingencies
|
||||||||
Stockholders' equity:
|
||||||||
Series C Convertible Preferred Stock, $.10 par value, 10,000,000 shares authorized; - and 2,103 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
|
-
|
1
|
||||||
Common Stock, $.001 par value, 150,000,000 shares authorized; 33,714,362 and 32,932,273 shares issued and outstanding at March 31, 2020 and December 31, 2019,
respectively
|
34
|
33
|
||||||
Additional paid-in capital
|
243,610
|
243,180
|
||||||
Accumulated deficit
|
(215,596
|
)
|
(214,561
|
)
|
||||
Total stockholders' equity
|
28,048
|
28,653
|
||||||
Total liabilities and stockholders’ equity
|
$
|
46,047
|
$
|
47,343
|
For the Three Months Ended
March 31,
|
||||||||
2020
|
2019
|
|||||||
Revenues, net
|
$
|
6,730
|
$
|
7,483
|
||||
Cost of revenues
|
2,331
|
2,874
|
||||||
Gross profit
|
4,399
|
4,609
|
||||||
|
||||||||
Operating expenses:
|
||||||||
Engineering and product development
|
292
|
304
|
||||||
Selling and marketing
|
2,953
|
3,066
|
||||||
General and administrative
|
2,102
|
2,480
|
||||||
|
5,347
|
5,850
|
||||||
Loss from operations
|
(948
|
)
|
(1,241
|
)
|
||||
|
||||||||
Other income (expense), net:
|
||||||||
Interest income (expense), net
|
1
|
(135
|
)
|
|||||
1
|
(135
|
)
|
||||||
Loss before income taxes
|
(947
|
)
|
(1,376
|
)
|
||||
Income tax (expenses) benefit
|
(88
|
)
|
43
|
|||||
Net loss
|
$
|
(1,035
|
)
|
$
|
(1,333
|
)
|
||
Loss attributable to common shares
|
$
|
(1,018
|
)
|
$
|
(1,216
|
)
|
||
Loss attributable to Preferred Series C shares
|
$
|
(17
|
)
|
$
|
(117
|
)
|
||
Loss per common share:
|
||||||||
Basic
|
$
|
(0.03
|
)
|
$
|
(0.04
|
)
|
||
Diluted
|
$
|
(0.03
|
)
|
$
|
(0.04
|
)
|
||
Shares used in computing loss per common share:
|
||||||||
Basic
|
33,164,321
|
30,703,501
|
||||||
Diluted
|
33,164,321
|
30,703,501
|
||||||
Loss per Preferred Series C share basic and diluted
|
$
|
(11.42
|
)
|
$
|
(14.72
|
)
|
||
Shares used in computing loss per basic and diluted Preferred Series C Shares
|
1,480
|
7,944
|
For the Three Months Ended
March 31,
|
||||||||
2020
|
2019
|
|||||||
Cash Flows From Operating Activities:
|
||||||||
Net loss
|
$
|
(1,035
|
)
|
$
|
(1,333
|
)
|
||
Adjustments to reconcile net loss to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
1,038
|
1,204
|
||||||
Amortization of right-of-use asset
|
79
|
93
|
||||||
Provision for doubtful accounts
|
2
|
(7
|
)
|
|||||
Loss on disposal of property and equipment and lasers placed in service
|
-
|
22
|
||||||
Stock-based compensation
|
430
|
323
|
||||||
Deferred taxes
|
88
|
(42
|
)
|
|||||
Amortization of debt discount
|
-
|
7
|
||||||
Amortization of deferred financing costs
|
-
|
27
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
1,176
|
(175
|
)
|
|||||
Inventories
|
(444
|
)
|
(327
|
)
|
||||
Prepaid expenses and other assets
|
43
|
142
|
||||||
Accounts payable
|
222
|
281
|
||||||
Other accrued liabilities
|
16
|
224
|
||||||
Other liabilities
|
(59
|
)
|
9
|
|||||
Operating lease liabilities
|
(60
|
)
|
(76
|
)
|
||||
Deferred revenues
|
(898
|
)
|
(36
|
)
|
||||
Net cash provided by operating activities
|
598
|
336
|
||||||
Cash Flows From Investing Activities:
|
||||||||
Lasers placed-in-service
|
(596
|
)
|
(434
|
)
|
||||
Net cash used in investing activities
|
(596
|
)
|
(434
|
)
|
||||
Net increase (decrease) in cash and cash equivalents and restricted cash
|
2
|
(98
|
)
|
|||||
Cash, cash equivalents and restricted cash, beginning of period
|
15,629
|
16,487
|
||||||
Cash, cash equivalents and restricted cash, end of period
|
$
|
15,631
|
$
|
16,389
|
||||
Cash and cash equivalents
|
$
|
8,150
|
$
|
16,389
|
||||
Restricted cash
|
7,481
|
-
|
||||||
$
|
15,631
|
$
|
16,389
|